| Proellex (telapristone) / AbbVie |
NCT00702702: Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids |
|
|
| Terminated | 3 | 56 | US | Proellex 25 mg, Proellex 50 mg, Placebo | Repros Therapeutics Inc. | Uterine Fibroids, Anemia | 08/09 | 08/09 | | |
NCT00735553: Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids |
|
|
| Terminated | 3 | 77 | US | Proellex, Telapristone acetate, Placebo, Sugar pill | Repros Therapeutics Inc. | Uterine Fibroids | 08/09 | 08/09 | | |
NCT00785356: Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids |
|
|
| Terminated | 3 | 8 | RoW | Proellex 25 mg, Telapristone acetate, Proellex 50 mg, Placebo, Sugar pill, Dummy | Repros Therapeutics Inc. | Uterine Fibroids, Anemia | 08/09 | 08/09 | | |
NCT00737282: Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids |
|
|
| Terminated | 3 | 175 | US | Proellex 25 mg, Telapristone acetate, Proellex 50 mg | Repros Therapeutics Inc. | Uterine Fibroids | 08/09 | 08/09 | | |
NCT00853567: Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids |
|
|
| Terminated | 3 | 71 | US | Proellex, Telapristone acetate, placebo | Repros Therapeutics Inc. | Uterine Fibroids | 08/09 | 08/09 | | |
NCT01069120: Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids |
|
|
| Terminated | 3 | 27 | US | Proellex, CDB-4124 | Repros Therapeutics Inc. | Uterine Fibroids | 08/09 | 08/09 | | |
NCT00874302: Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms |
|
|
| Withdrawn | 3 | 0 | US, RoW | Proellex, Telapristone acetate | Repros Therapeutics Inc. | Uterine Fibroids | | | | |
